Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.54 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12339943 | 0.86 | SCD5 (0.49) | ANPEPDGAT2TDP1SCD5HTT | |
| SCHEMBL12339937 | 0.85 | HDAC1 (0.50) | HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL13819984 | 0.83 | MAOB (0.54) | HDAC1HDAC8HDAC6 | |
| SCHEMBL12902828 | 0.79 | MAOB (0.48) | ANPEPDGAT2HDAC1HDAC8HDAC6 | |
| SCHEMBL12339928 | 0.79 | TUBB4A (0.54) | ANPEPDGAT2 | |
| SCHEMBL4895576 | 0.79 | MEN1 (0.55) | DGAT2TDP1HTTMEN1KMT2A | |
| SCHEMBL12339960 | 0.78 | HDAC1 (0.52) | HDAC1HDAC8HDAC6 | |
| SCHEMBL4896516 | 0.76 | MAOB (0.54) | DGAT2TDP1HTTMEN1KMT2A | |
| SCHEMBL12339963 | 0.76 | TUBB4A (0.57) | ANPEPDGAT2 | |
| SCHEMBL12339959 | 0.74 | TUBB4A (0.51) | ANPEPDGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729270-B2 | Anti-cancer compounds, synthesis thereof, and methods of using same | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729270-B2 | Anti-cancer compounds, synthesis thereof, and methods of using same | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120289704-A1 | ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289704-A1 | ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289704-A1 | ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME | MCL1, BRDT, GLS | ANPEP 3543/4885DGAT2 2408/4885TDP1 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.